Richard Natale, MD
Urology · Concord, NCNPI 1700957677
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,230 of the $107,876 with a category attached, or 63.2%. Boston Scientific accounts for 90.2% of it on its own, with 20 other manufacturers making up the rest. Among urology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 305 payments — averaging $353.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$97K
- Dendreon Pharmaceuticals LLC$2K
- Axonics, Inc.$2K
- Janssen Scientific Affairs, LLC$2K
- Medtronic$2K
- Tolmar Pharmaceuticals, Inc.$1K
- plus $2K from 15 others
Across 6 payments — averaging $1680.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$10K
What the payments were for
- Consulting fees$17,38316%
- Speaking & faculty fees$68,23063%
- Travel & lodging$14,16513%
- Food & beverage$7,9207%
- Education$1780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 220 | $97,345 |
| Dendreon Pharmaceuticals LLC | 8 | $2,110 |
| Axonics, Inc. | 9 | $1,921 |
| Janssen Scientific Affairs, LLC | 2 | $1,768 |
| Medtronic(2 entities) | 19 | $1,573 |
| Tolmar Pharmaceuticals, Inc. | 4 | $1,195 |
| Procept Biorobotics Corporation | 6 | $1,110 |
| Astellas Pharma US Inc | 9 | $202 |
| Johnson & Johnson(2 entities) | 8 | $126 |
| Endo Pharmaceuticals Inc. | 4 | $124 |
| Tolmar, Inc. | 2 | $91 |
| Neotract Inc. | 1 | $58 |
| Laborie Medical Technologies Corp. | 2 | $43 |
| Antares Pharma, Inc. | 2 | $42 |
| Pfizer | 3 | $41 |
| Peerless Surgical Inc. | 1 | $40 |
| Bayer | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| 180 Medical, Inc. | 1 | $19 |
| Coloplast | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$20,766
- GENERAL ERECTILE DYSFUNCTION$15,695
- AdVance XP$14,241
- TACTRA$11,341
- AMS 700 CXR RTE KIT$9,200
- GENERAL BPH$5,528
- REZUM$4,150
- GENERAL - THERAPIES$2,449
- AMS 700$2,111
- SPACEOAR$1,925
- PROVENGE$1,918
- Axonics$1,644
- Bulkamid$1,644
- INTERSTIM$1,201
- ELIGARD$1,130
- Erleada$1,010
- AquaBeam Robotic System$940
- SPACEOAR VUE$600
- Watchman$411
- Lumenis Pulse 50H$200
How this compares
$107,876 in reported general payments places this provider in the 95th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 81 | $1,131,064 |
| OrgovyxRelugolix | 47 | $123,172 |
| MyrbetriqMirabegron | 79 | $81,564 |
| GemtesaVibegron | 52 | $43,260 |
| Tamsulosin Hcl | 369 | $5,089 |
| Testosterone | 30 | $3,849 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 21 | $3,843 |
| Potassium Citrate ErPotassium Citrate | 21 | $2,761 |
| Testosterone Cypionate | 59 | $2,399 |
| Silodosin | 30 | $2,153 |
| Methenamine Hippurate | 37 | $1,709 |
| Finasteride | 111 | $1,075 |
| Cabergoline | 16 | $869 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 30 | $700 |
| Desmopressin Acetate | 11 | $501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $202 | $1,212,628160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 urology providers in North Carolina.
Other urology in Concord
- Tom FloydConcord$12K
- Robert LippittSmithfield$11.4M
- Michael KennellyCharlotte$1.3M
- John KasparRaleigh$1.1M
- Judd MoulDurham$1M
- Daniel GeorgeDurham$1M
- Scott MacdiarmidGreensboro$774K
- Glenn PremingerDurham$736K
- Michael LipkinDurham$293K
- Culley CarsonChapel Hill$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.